Venture-Backed Startups
56,712 companies with verified investor relationships.
0 investors
0 investors
Attn: Grace develops plant-based, skin-safe incontinence pads, liners, and body care products designed for comfort and leak protection. The company focuses on eco-conscious manufacturing with sustainable materials and CO2 neutral production.
4 investors
0 investors
0 investors
AttoTude develops optical interconnect technology for data centers to support artificial intelligence and exascale computing applications.
2 investors
Attovia develops precision biologics using its ATTOBODY platform for patients with immune-mediated diseases. The company creates novel complex biologic medicines through modular protein design.
4 investors
2 investors
0 investors
Attune provides software supply chain security by enabling traceability of code back to its author, device, and keystroke to prevent CI/CD pipeline attacks and secure the build process.
2 investors
0 investors
1 investor
Attune Health combines genomics, proteomics, and metabolomics with functional nutrition and lifestyle modification to treat people with autoimmune and inflammatory diseases. The company leverages precision science and technology to improve patient outcomes in this healthcare sector.
1 investor
Attunement provides AI-powered tools for interpreting complex medical records and supporting clinical documentation workflows in healthcare settings. The platform integrates with EHR systems and maintains patient context while generating report-ready outputs with built-in clinician oversight.
1 investor
0 investors
0 investors
Atum Works develops scalable 3D lithography technology capable of printing metal structures with submicron resolution for advanced manufacturing applications.
3 investors
Atum Labs is a technology company developing software products and offering custom software development services. Details on its specific products have not yet been published.
1 investor
atVenu provides technology tools and services for live events, including point-of-sale and operational software designed to handle high-volume scenarios at festivals, concerts, and tours.
1 investor
0 investors
0 investors
1 investor
0 investors
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.
2 investors